Welcome to our dedicated page for Biocept news (Ticker: BIOC), a resource for investors and traders seeking the latest updates and insights on Biocept stock.
Biocept, Inc. (symbol: BIOC) is a leading molecular oncology diagnostics company, specializing in the analysis of circulating tumor-associated DNA. The company focuses on both circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) in plasma. Biocept’s mission is to enhance cancer patient outcomes through the advancement of oncology diagnostics.
Utilizing patented and innovative technologies, Biocept delivers clinically relevant prognostic and predictive assessments to physicians, aiding in the treatment course for cancer patients. Their key offering, the Target Selector™ technology, is renowned for its ability to consistently capture extremely rare cells, which may be found in as few as 1 in 50-100 billion blood cells. This technology allows for precise biomarker analysis, assisting in better disease management and treatment decisions.
Beyond direct patient services, Biocept extends its expertise to other laboratory testing providers, academic institutions, research organizations, and biopharmaceutical companies. They play a vital role in clinical trial support, contributing to the development of new cancer therapies.
Biocept’s recent achievements highlight their commitment to innovation and excellence in oncology diagnostics. The company continually strives to expand its technological capabilities and partnerships, ensuring the delivery of high-quality diagnostics solutions to the oncology community.
Biocept, Inc. (Nasdaq: BIOC) announced significant milestones as of December 14, 2020. The company has processed over 150,000 COVID-19 RT-PCR test samples, reporting most results within 48 hours. Additionally, Biocept successfully transitioned to a new corporate headquarters and molecular laboratory in San Diego, designed for operational efficiency and expected to reduce facility costs by 20% annually. All operations in the new facility are fully functional, enabling continued service in oncology and COVID-19 testing.
Biocept, Inc. (Nasdaq: BIOC) announced promising results from a study indicating the effectiveness of its Target Selector™ liquid biopsy in monitoring HER2 alterations in metastatic breast cancer patients. Conducted at Johns Hopkins, the study showed Target Selector™ to be highly accurate and less invasive than traditional tissue biopsies. Dr. Vered Stearns highlighted the importance of this method for tracking treatment response and identifying potential therapy adjustments. The findings were presented at the 2020 San Antonio Breast Cancer Symposium, emphasizing Biocept's commitment to enhancing patient outcomes through advanced diagnostics.
EIR Healthcare has launched MedModLabs, a modular healthcare initiative aimed at enhancing COVID-19 testing access through mobile, prefabricated sampling facilities. Developed in collaboration with Biocept (Nasdaq: BIOC), MedModLabs offers non-invasive oral swab tests with results in 1-2 business days and no prescription required. Despite a national average of 1.7 million daily tests, demand exceeds supply, particularly during holiday surges. MedModLabs is committed to providing 10% of its tests to underserved communities, and is currently operational in the greater Philadelphia area.
Biocept, Inc. (Nasdaq: BIOC) announces positive results from a study evaluating its Target Selector™ CSF assays for detecting circulating tumor cells (CTCs) in cerebrospinal fluid (CSF) of patients with metastasized lung or breast cancer. The study, presented at the SNO2020 Virtual Conference, highlights the assays' sensitivity compared to traditional CSF cytology, which has limited accuracy. This minimally invasive technology could enhance patient monitoring and therapy selection while avoiding surgical risks. Biocept continues to progress in neuro-oncology, with this being the second significant conference to showcase their findings.
Biocept, Inc. (Nasdaq: BIOC) announced that results from a study using its Target Selector™ testing will be presented at the 2020 San Antonio Breast Cancer Symposium on December 9, 2020. The study evaluates liquid biopsies for monitoring HER2 status in metastatic breast cancer, addressing the challenges of obtaining tissue samples. Dr. Vered Stearns of Johns Hopkins will present findings that could inform treatment options for HER2-positive patients as their tumors progress.
Biocept, Inc. (Nasdaq: BIOC) reported a significant increase in third-quarter revenues for 2020, reaching $6.6 million, up from $1.5 million in Q3 2019, thanks to COVID-19 RT-PCR testing. The company processed over 52,993 samples during the quarter. Despite a net loss of $4.9 million, improvements in oncology testing volumes were noted, particularly in neuro-oncology. Biocept has also expanded its patent portfolio and received positive coverage for its Target Selector™ liquid biopsy assays, indicating strong future potential in oncology diagnostics.
Biocept, Inc. (Nasdaq: BIOC) announced it has processed over 100,000 COVID-19 samples through its RT-PCR technology at its CLIA-certified lab. The company provides testing for various clients, primarily in California, and aims to return results within 48 hours. CEO Michael Nall stated that the COVID-19 testing is expected to have a significant positive impact on revenues for 2020 and into 2021. Biocept also specializes in molecular diagnostics for different cancers, utilizing their proprietary liquid biopsy technology for patient monitoring and treatment.
Biocept, Inc. (NASDAQ: BIOC) announced its receipt of Hong Kong Patent No. 1188285 for methods and reagents that enhance the detection of circulating tumor cells (CTCs). This patent complements Biocept's existing technologies, which include antibody-based CTC enrichment and a patented blood transport tube for analysis. President and CEO Michael Nall highlighted that this patent supports the company's strategy for global growth, increasing its intellectual property portfolio to 44 patents focused on molecular diagnostics.
Biocept, Inc. (Nasdaq: BIOC) announced the award of Japanese Patent No. 6771010 for its devices and methods used to capture and analyze circulating tumor cells (CTCs) from biological samples. This patent enhances Biocept's intellectual property portfolio and enables the detection of various tumor types through binding entities such as antibodies. The technology supports existing platforms like their blood collection tube and Target Selector™ circulating DNA analysis, potentially leading to licensing opportunities with other companies.
Biocept, Inc. (Nasdaq: BIOC) will announce its financial results for Q3 2020 on November 12, 2020, after market close. The company will host a conference call at 4:30 PM ET to discuss the results and take questions from investors. Biocept specializes in molecular diagnostic tests for cancer, leveraging its proprietary Target Selector™ liquid biopsy technology to provide actionable insights for treatment and monitoring. The firm also supports COVID-19 testing initiatives. Investors can pre-register for the call to streamline access.
FAQ
What is the market cap of Biocept (BIOC)?
What does Biocept, Inc. specialize in?
What is Biocept's mission?
What technology is Biocept known for?
Who can benefit from Biocept's services?
What are circulating tumor cells (CTCs)?
How does Biocept’s technology assist physicians?
Does Biocept support clinical trials?
What recent achievements has Biocept made?
Where is Biocept's technology applied?
How does Biocept’s Target Selector™ technology work?
